In the first three posts in this series, we covered the manufacturing landscape for advanced therapies, the importance of modality-specific expertise and development integration,...
Read More →July 14, 2026
In the previous post, we covered the two structural criteria that most reliably distinguish a translational development partner...
Read more →July 06, 2026
In the first post in this series, we looked at the manufacturing landscape for advanced therapies and what the FDA data tells us...
Read more →June 18, 2026
AAV is one of the most widely used delivery platforms in gene therapy, supporting approved treatments for inherited retinal...
Read more →May 28, 2026
Last November we published POSTmark CAR-T: Delivering Therapies Without Delay, arguing that manufacturing continuity—not...
Read more →April 27, 2026
At Advanced Therapies Week 2026, our Chief Technology Officer, Gregg Nyberg, joined a panel of industry leaders to discuss how...
Read more →April 02, 2026
Your science is ready.
The mechanism is well-characterized, the preclinical data is compelling, and the clinical development...
Read more →February 26, 2026
Extracellular vesicles have been a subject of scientific fascination for decades. For most of that time, they were studied...
Read more →January 22, 2026
In today’s rapidly evolving biotech landscape, the efficient flow and integration of data across various systems and functions...
Read more →December 15, 2025
Cell and gene therapies (CGTs) have advanced from conceptual promise to clinical reality, with dozens of approved products and...
Read more →